INS and Hyperglycemia: In a small study of 25 patients with hyperglycaemia and hospitalised with COVID-19, use of intravenous insulin to achieve a mean glucose of 7.69 ± 1.85 mmol/L (vs 10.65 ± 0.84 mmol/L in the no insulin infusion group) was associated with reduced IL-6 and D-dimer levels and improved composite end-point (admission to an ICU, the use of mechanical ventilation, or death) (23).